Secukinumab, marketed as Cosentyx, has several patents protecting its intellectual property. These patents cover various aspects of the drug, including its composition, methods of use, and manufacturing processes.
When are Secukinumab patents set to expire?
The patent expiration dates for secukinumab vary by patent and region. For example, U.S. Patent No. 8,927,503, which pertains to secukinumab, is listed with an expiration date of January 31, 2024 [1]. However, other patents may extend protection further. Information on specific patent expiry timelines can be found on resources like DrugPatentWatch.com [2].
What is secukinumab used for?
Secukinumab is a monoclonal antibody used to treat several inflammatory conditions. It is approved for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and active psoriatic arthritis in pediatric patients [3].
How does secukinumab work?
Secukinumab is an interleukin-17A (IL-17A) inhibitor. By blocking IL-17A, a key cytokine in the inflammatory process, secukinumab helps reduce inflammation associated with the conditions it treats [3].
Who manufactures secukinumab?
Novartis manufactures and markets secukinumab under the brand name Cosentyx [3].
What are the competitors to secukinumab?
Other biologic drugs target similar inflammatory pathways and are considered competitors to secukinumab. These include medications like ustekinumab (Stelara), ixekizumab (Taltz), and adalimumab (Humira), among others [4].
Can biosimilars be made before patent expiry?
Generally, biosimilar versions of biologic drugs cannot be approved or marketed until the relevant patents and exclusivity periods have expired. This protects the innovator company's investment in drug development. The exact timing for potential secukinumab biosimilars would depend on the expiration of all applicable patents and regulatory exclusivities.
What are the potential risks and side effects of secukinumab?
Secukinumab can cause serious side effects, including infections, and may increase the risk of certain cancers [3]. Patients may experience side effects such as upper respiratory tract infections, headache, and nausea [5].
What is the patent landscape for biologics like secukinumab?
The patent landscape for biologic drugs is complex, with multiple patents often covering different aspects of the drug. This can include patents on the drug substance itself, formulations, methods of manufacturing, and methods of treatment. These patents are crucial for pharmaceutical companies to recoup the substantial costs of developing and bringing biologic therapies to market. For a comprehensive view of secukinumab's patent situation, resources tracking drug patents are available [2].
---
Sources:
1. U.S. Patent 8,927,503
2. https://drugpatentwatch.com/
3. Cosentyx (secukinumab) Prescribing Information
4. Analysis of secukinumab market and competitors
5. Common side effects of Cosentyx